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Abstract: As a result of their potent antigen-pre-
sentation function, dendritic cells (DC) are impor-
tant tools for cell therapy programs. In vitro-gen-
erated DC from enriched CD34 hematopoietic
stem cells (HSC; enriched CD34 DC) have already
proven their efficiency in Phase I/II clinical trials.
Here, we investigated whether enrichment of
CD34 HSC before the onset of culture was abso-
lutely required for their differentiation into DC.
With this aim, we developed a new two-step culture
method. PBMC harvested from G-CSF-mobilized,
healthy patients were expanded for 7 days during
the first step, with early acting cytokines, such as
stem cell factor, fetal liver tyrosine kinase 3 ligand
(Flt-3L), and thrombopoietin. During the second
step, expanded cells were then induced to differ-
entiate into mature DC in the presence of GM-CSF,
Flt-3L, and TNF- for 8 days, followed by LPS
exposure for 2 additional days. Our results showed
that the rate of CD34/CD38/lineageneg cells
increased 19.5  10-fold (meanSD) during the
first step, and the expression of CD14, CD1a,
CD86, CD80, and CD83 molecules was up-regu-
lated markedly following the second step. When
compared with DC generated from enriched
CD34 cells, which were expanded for 7 days
before differentiation, DC derived from nonen-
riched peripheral blood stem cells showed a similar
phenotye but higher yields of production. Accord-
ingly, the allogeneic stimulatory capacity of the
two-step-cultured DC was as at least as efficient as
that of enriched CD34 DC. In conclusion, we re-
port herein a new two-step culture method that
leads to high yields of mature DC without any need
of CD34 HSC enrichment. J. Leukoc. Biol. 81:
957–967; 2007.
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INTRODUCTION
Dendritic cells (DC) represent a rare population of highly
potent APC. They are derived from CD34 bone marrow stem
cells and can be generated in vitro from blood monocytes in the
presence of GM-CSF and IL-4 (Mo-DC) [1] or from CD34
hematopoietic stem cells (HSC) in the presence of GM-CSF
and TNF- (CD34 DC) [2]. They play a major role in the
processing and presentation of antigens to different immune
cells, and they have the unique capacity to prime naı̈ve T
lymphocytes. To play this role, DC up-regulate the expression
of CD1a, HLA Class II, CD80, CD86, and CD83 molecules.
This differentiation and maturation process promotes the po-
larization of naı̈ve T cells and activates antigen-specific T
lymphocytes [3].
Generation of DC from CD34 HSC gives rise to two DC
subpopulations: CD14CD1a– cells, which are precursors of
interstitial DC, and CD1aCD14– cells, which are precursors
of Langerhans cells [2, 4–8]. DC can also be generated in vitro
from monocyte precursors. Mo-DC represent a homogeneous
population of immature DC, resembling interstitial DC [1,
9–11]. Although Mo-DC require exposure to additional factors
to mature fully, CD34 DC partially express low levels of CD83,
which is a maturation marker. The presence of TNF-, an
activation factor of DC [2], from the onset of culture could
account for the presence of this marker.
Vaccines against cancer aim to induce tumor-specific effec-
tor T cells, which can reduce tumor mass, as well as tumor-
specific memory T cells, which can control tumor relapse.
Owing to their capacity to regulate T cell immunity, DC are
being used increasingly as adjuvants for vaccination, and the
immunogenicity of antigens delivered by these DC has now
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been shown in patients with cancer. In particular, CD34 DC
have proven to be efficient adjuvants in a Phase I/II trial, which
resulted in clinical and immunological responses in 10 out of
17 patients suffering from metastatic melanoma [12–14].
Recently, two different studies have demonstrated that high
yields of functional DC from human umbilical cord blood or
bone marrow CD34 cells can be generated by using a two-
step culture method. Enriched CD34 hematopoietic progen-
itor cells were expanded during the first step of culture [15, 16]
using reported expansion protocols [17, 18] and then induced
to differentiate into DC during the second step. However, this
methodology requires high numbers of CD34 HSC and costly
enrichment protocols. Therefore, here, we addressed whether
enrichment of CD34 HSC before expansion was absolutely
required for getting high numbers of DC. Reported herein is a
new two-step culture method, whereby nonenriched PBMC,
harvested from G-CSF-mobilized patients, are expanded and
then differentiated into DC. The efficacy of this process was
evaluated by comparing, at phenotypical and functional levels,
these two-step-cultured DC with the classical, enriched CD34
DC reported by Caux et al. [2] and with enriched, two-step,
cultured DC.
MATERIALS AND METHODS
Culture media and cytokines
Complete medium (CM) used was RPMI 1640 (Eurobio, France), supple-
mented with 2 mM L-glutamine and 100 IU/ml penicillin-streptomycin (Gibco,
Grand Island, NY, USA) and 10% heat-inactivated FBS (Gibco). IMDM
(Gibco), supplemented with 10% heat-inactivated FBS, was used for expan-
sion. Recombinant human stem cell factor (rhSCF), thrombopoietin (TPO),
fetal liver tyrosine kinase 3 ligand (Flt-3L), GM-CSF, and TNF- were
purchased from R&D Systems (Minneapolis, MN, USA).
Enrichment of CD34 HSC from G-CSF-
mobilized peripheral blood
After obtaining informed consent, healthy donors received rhG-CSF (Grano-
cyte or Neupogen), 10 g/kg/day s.c., for 5 days for peripheral blood stem
cell mobilization and then underwent apheresis for 2 consecutive days to
collect mobilized CD34 HSC. Mononuclear cells (MNC) were isolated from
mobilized peripheral blood by Ficoll density gradient centrifugation and were
split in two parts. One part was used to purify CD34 cells by using
anti-CD34-coated magnetic beads (Miltenyi Biotec, Inc., Germany), relative to
Miltenyi protocol. The purity of the CD34 fractions was controlled. CD34-
enriched HSC were then used immediately in the two-step culture method or
frozen until use in the one-step culture method.
Differentiation of enriched CD34 HSC into DC in
the classical, one-step culture method
As described previously by Caux et al. [2] and Banchereau et al. [12], enriched
CD34 HSC, issued from the same healthy donors, were thawed and cultured in
parallel with Day 7-expanded, nonenriched HSC. Cells (2106) were seeded
in a 25-cm2 flask in 5 ml CM supplemented with 50 ng/ml GM-CSF, 10 ng/ml
TNF-, and 100 ng/ml Flt-3L. At Day 3, cultures were fed by adding 1.5 ml
fresh medium with cytokines. At Day 5, cultures were split into two flasks with
fresh medium and cytokines. At Day 8, half of the cells were harvested for
analyses, and half of the cells were induced to mature by exposure for 48 h to
100 ng/ml LPS (Sigma Chemical Co., St. Louis, MO, USA).
Expansion of nonenriched HSC and enriched
CD34 HSC in the first culture step
The unfractionated MNC (nonenriched HSC) or enriched CD34 HSC from the
same healthy donors were expanded in parallel. Nonenriched, G-CSF-mobi-
lized MNC (3106) or 2  105 enriched CD34 HSC were seeded in a 25-cm2
flask and cultured in IMDM media supplemented with 10% heat-inactivated
FBS. The cells were expanded for 7 or 14 days in the presence of 50 ng/ml
SCF, 10 ng/ml TPO, and 50 ng/ml Flt-3L. The medium was refreshed regularly
by partial depletion throughout the culture period.
Differentiation of expanded, nonenriched HSC or
expanded, enriched CD34 HSC into DC in the
second culture step
Day 7-expanded, enriched CD34 HSC, issued from the same donor, were
cultured in parallel with Day 7-expanded, nonenriched HSC. Cells (2106)
were seeded in a 25-cm2 flask in 5 ml CM supplemented with 50 ng/ml
GM-CSF, 10 ng/ml TNF-, and 100 ng/ml Flt-3L. At Day 3, cultures were fed
by adding 1.5 ml fresh medium with cytokines. At Day 5, cultures were split
into two flasks with fresh medium and cytokines. At Day 8, half of the cells
were harvested for analyses, and half of the cells were induced to mature by
exposure for 48 h to 100 ng/ml LPS (Sigma Chemical Co.).
Flow cytometry
The antibodies used for flow cytometry were FITC- or PE-conjugated mouse
antihuman CD34, lineage (Lin; including CD3, CD14, CD16, CD19, CD20,
CD56), CD1a, HLA-DR, CD14, CD80, CD86, and CD83. The mAb against
CD34, CD38, Lin, and CD1a were purchased from BD PharMingen (San Diego,
CA, USA). The mAb against HLA-DR, CD14, CD80, CD86, and CD83 were
purchased from Immunotech (Marseille, France). Cultured cells were col-
lected, washed twice, and then resuspended in 200 l PBS containing 0.1%
BSA (PBSA). Cells were stained with specific labeled antibodies or appropriate
isotypic controls. They were incubated on ice for 30 min and washed with
PBSA and then fixed with 1% paraformaldehyde solution. Analyses were
performed using a FACScan (BD Medical System, Sandy, UT, USA) and the
WinMDI software (Version 2.8, Scripps Institute, La Jolla, CA, USA). Data
were expressed as percent mean positivity  SD.
MLR
Cells were collected at the end of the second period of culture and used to
stimulate fully mismatched T lymphocytes. Graded doses of irradiated, stim-
ulating cells were seeded with 1  105 allogeneic T lymphocytes in round-
bottom microwell tissue-culture plates in complete RPMI 1640 with 10%
human AB serum. Thymidine incorporation was measured at Day 5, following
an 18-h pulse with 1 Ci 3H-thymidine.
Statistical analysis
Data were expressed as percent mean positivity  SD. The paired Student’s
t-test was performed to compare two or more mean values. A probability of
null hypothesis less than 5% (P0.05) was considered statistically signif-
icant.
RESULTS
Expansion of HSC from G-CSF-mobilized MNC
without prior CD34 enrichment and
characterization of the best period
for DC generation
We performed three different experiments to analyze the ki-
netics of expansion of nonenriched CD34/CD38/Linneg
cells. Nonenriched, G-CSF-mobilized MNC were cultured in
the presence of SCF, TPO, and Flt-3L for 7 and 14 days,
respectively. Nonenriched, G-CSF-mobilized MNC were
cultured in the presence of SCF, TPO, and Flt-3L for 7 and
14 days, respectively. The phenotype of the expanded cells
was analyzed by staining them for the CD34, CD38, and Lin
markers to detect the CD34/CD38/Linneg cells, which
represent short-term, hematopoietic precursors in human. A
958 Journal of Leukocyte Biology Volume 81, April 2007 http://www.jleukbio.org
representative experiment is shown in Figure 1, and the
three experiments are reported in Table 1A. As shown in
Figure 1, we observed that the percentage of CD34/
CD38/Linneg cells increased markedly from 3.5% at Day 0
to 30% at Day 7. However, this increase was transient, as
the rate of short-term hematopoietic precursors decreased
drastically at Day 14. Accordingly, the CD34 absolute cell
number increased strongly during the first week of culture to
reach a 19.5  10-fold increase at Day 7 but subsequently
dropped at Day 14 (Table 1A). Therefore, we defined the
optimum period for expansion of G-CSF-mobilized HSC to be
at Day 7 of the first culture step. As shown in Table 1A and
Table 1B, this time-frame was used in the following experi-
ments, unless otherwise stated.
Fig. 1. CD34CD38/Linneg phenotype of Day 7- or Day 14-expanded HSC from nonenriched, G-CSF-mobilized MNC, which were expanded for 7 and 14 days,
respectively, by culture with SCF, TPO, and Flt-3L. Expanded HSC were labeled with CD34-APC, CD38-PE, and Lin-FITC antibodies and analyzed in a
three-color flow cytometer. Quadrants were set based on the isotype-matched control dot plot, and 10,000 events were acquired. The percentage of positive
CD34CD38 cells is shown in each dot-plot profile. The CD34CD38 population was then gated to analyze Lin expression in these cells. This phenotype
is representative of three individual experiments.
TABLE 1A. Expansion Rates of HSC (106) and CD34 Cells (104) from Nonenriched or CD34-Enriched, G-CSF-Mobilized MNC
No.

























Nonenriched Ia-1 3 3.50% 10.5 5.8 32% 186 6.1 1.50% 9.1
Nonenriched Ia-2 3 1.80% 5.4 2.6 30% 78 16.9 4.30% 72.7
Nonenriched Ia-3 3 2.30% 6.9 3.3 26% 86 11.1 ND ND
Mean  SD 3 2.5  0.9% 7.6  2.6 3.9  1.7 29  3% 117  60 11.4  5.4 2.9  1.9% 40.9  44.7
CD34-enriched Ia-1 0.2 67.50% 13.5 1.8 73.30% 131.9 7.2 5.3 38.2
CD34-enriched Ia-2 0.2 98% 19.6 2 72.20% 144.4 5.8 ND ND
Mean  SD 0.2 83  22% 16.6  4.3 1.9  0.14 72.8  0.8% 138.2  8.8 6.5  1 5.3% 38.2
Data are from three individual experiments with nonenriched (n3) or enriched CD34 (n2) cells issued from the same G-CSF-mobilized patients. Total MNC,
percentage of CD34 cells, and absolute number of CD34 cells during the first culture step are analyzed at Days 0, 7, and 14. ND, Not done.
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Generation of DC from expanded HSC by the
two-step culture method results in more
differentiated DC as compared with the
standard method
We then investigated whether the HSC enrichment step was
required before differentiating HSC into DC. Therefore, Day
7-expanded cells from nonenriched cultures were washed ex-
tensively and further cultured with GM-CSF, Flt-3L, and
TNF- for 8 days during a second step of culture. Enriched
CD34 HSC from the same donor were cultured in the same
conditions in parallel, to compare the phenotypes and func-
tions of the DC obtained by these two methods. As shown in a
representative experiment (Fig. 2), cells obtained by both
methods expressed CD1a and CD14, two markers of CD34 DC.
TABLE 1B. Expansion of HSC (106) and CD34 Cells (104) from Nonenriched and from Enriched CD34,
G-CSF-Mobilized MNC in the First Culture Step for DC Generation
No.
Day 0 first culture step Day 7 first culture step
MNC (106) % of CD34
Absolute number of
CD34 (104) HSC (106) % of CD34
Absolute number of
CD34 (104)
Nonenriched Ib-1 3 2% 6 8 21.70% 173.6
Nonenriched Ib-2 3 2.10% 6.3 8 32% 256
Mean  SD 3 2  0.1% 6.1  0.2 8 26.9  7.3% 215  58
CD34-enriched Ib-1 0.2 65% 13 0.5 72.70% 36.5
CD34-enriched Ib-2 0.2 85% 14 0.5 73.30% 36.7
Mean  SD 0.2 75  14% 13.5  0.7 0.5 73  0.4% 36.6  0.1
Data are from two individual experiments with nonenriched (n  2) or enriched CD34 HSC (n  2) cells issued from the same G-CSF-mobilized patients.
Total MNC, percentage of CD34 cells, and absolute number of CD34 cells during the first culture step are measured at Days 0 and 7.
Fig. 2. Comparison of the phenotype of DC generated by the nonenriched, two-step culture method with that of classical, enriched CD34 DC in a one-step culture
method. At the end of the second step of culture, DC were stained for CD1a and CD14 expression. The levels of expression of these molecules were compared
by cytofluorometry with that of enriched CD34 DC. The subpopulation of CD14CD1a– cells represents precursors of interstitial DC, whereas the subpopulation
of CD1aCD14– represents precursors of Langerhans cells. This phenotype is representative of five individual experiments. Quadrants were set up on the
isotype-matched control dot plot, and 10,000 events were acquired. The percentage of nongated cells is shown in the dot-plot profiles. (B) The percentages of
CD1a cells and CD14 cells, which were obtained from the two different culture methods, were calculated. Results are represented as mean percent  SD of
five separate experiments. *, P  0.05.
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It is interesting that the percentage of CD14 cells or CD1a 
cells was higher when DC were generated by the nonenriched,
two-step culture method, as compared with the standard one
(Fig. 2). Few cells were double-positive for these two markers.
Nevertheless, the percentage of double-positive cells was
higher in the nonenriched, two-step, cultured DC (4.3–14.1%)
than the enriched CD34 DC population (0.9–5.1%). Alto-
gether, these data show that the nonenriched, two-step, culture
method allows efficient generation of cells with a DC pheno-
type. As the only difference between the two cultures was the
first step of HSC expansion, our results demonstrate that the
enrichment step could be replaced by an expansion step.
Cells generated by the nonenriched, two-step
culture method differentiate into DC faster than
those from the classical, one-step
culture method
The higher levels of CD14 and CD1a DC, which were gen-
erated by the nonenriched, two-step culture method, led us to
question whether the first step of culture could have influenced the
capacity of HSC to differentiate into DC during the second step or
whether CD14 and CD1a cells were already present at Day 0
of the differentiation step. Therefore, a time-course of DC gener-
ation was performed. Cells were harvested at Days 3, 5, and 8 of
the second step of culture and were analyzed for their levels of
CD1a and CD14 molecule expression. As shown in Figure 3,
cells derived from enriched CD34 HSC did not express any of
these two DC markers at Days 0, 3, and 5 of the DC differentiation
step. Indeed, cell surface expression of CD1a and CD14 mole-
cules on these cells did not appear until Day 8 of the second
culture step (Fig. 3). In contrast, cells, which were expanded
previously during a first step of culture, already showed some
nonsignificant levels of CD14 and CD1a surface molecule expres-
sion (1.9% and 0.8% of ungated cells, respectively) at Day 7 of the
first step or Day 0 of the differentiation step. At Day 5 of the
differentiation step or Day 12 of the DC total culture, multiple,
nonadherent cell aggregates were observed and expanded progres-
sively up to Day 8 of the differentiation step. These cell aggregates
were floating and showed typical dendrites under an inverted
microscope. In accordance with these observations, CD1a- and
CD14-positive cells appeared as early as Day 5, and their rates
increased up to Day 8 of the second culture step (Fig. 3). These
CD1a and CD14 cells did not express CD34 or CD38 (data
not shown), assessing that these cells were not HSC precursors.
Therefore, this kinetics study suggests an earlier differentiation of
HSC into DC with the nonenriched, two-step culture method as
compared with a classical method using CD34-enriched cells.
The nonenriched, two-step culture method leads
to higher rates of mature DC than the enriched
CD34 standard method
As DC appeared as soon as Day 5 of the second step of culture
and showed dendrites under an inverted microscope, we then
Fig. 3. Kinetics of DC generation by the nonenriched, two-step culture method, as compared with that of one-step, cultured, enriched CD34 DC. Cells harvested
at Day 7 of the first culture step or enriched CD34 HSC were induced to differentiate into DC in the presence of the appropriate cytokines. They were then
harvested at Days 3, 5, and 8 of the DC differentiation step and evaluated for their expression of CD1a and CD14 on their cell surface. These data are from one
experiment representative of two individual experiments.
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investigated whether the two-step culture method could lead to
generation of higher rates of mature DC, as compared with the
CD34-enriched standard method. Therefore, we harvested DC
at Day 8 of the second step, washed them, and cultured them
for 48 h with LPS to induce their maturation. As shown in
Figure 4, the levels of T cell costimulatory molecules (CD80,
CD86) at Day 8 of culture, before induction of maturation, were
higher in immature DC generated by the nonenriched, two-step
culture method than in enriched CD34 DC. In addition, we
observed the presence of significant levels of CD83 molecule
expression in these cells (Fig. 4, upper rows). Following LPS
exposure, CD80, CD86, and CD83 molecules were up-regu-
lated in both DC subtypes, but overall, CD80, CD86, and CD83
molecules were expressed at higher levels in the DC obtained
by the nonenriched, two-step culture method as compared with
enriched CD34 DC. Thus, up to 34% of the nonenriched,
two-step, cultured DC were positive for the CD83 marker, as
compared with 11% for enriched CD34 DC (Fig. 4, lower rows).
The mean of mature DC in the nonenriched, two-step culture
method was of 25% versus 16% in the enriched, one-step
culture method (P0.05, n5; Table 2A). Therefore, these
results suggest that the nonenriched, two-step culture method
leads to more mature DC than the enriched CD34, one-step
culture method.
The allostimulatory capacity of DC generated by
the nonenriched, two-step culture method is at
least as high as that of enriched CD34 DC
We then evaluated the allostimulatory capacity of the DC
generated by the nonenriched, two-step culture method, in
comparison with that of one-step, cultured, enriched CD34 DC.
The mean value of four independent MLR assays (four at Day
8 and four at Day 10) showed a trend toward higher prolifer-
Fig. 4. DC generated by the nonenriched, two-step culture method are more
differentiated and matured faster than one-step, cultured, enriched CD34 DC. At
Day 8, cells were induced to mature by exposure to 100 ng/ml LPS for 48 h.
Maturation of DC was phenotypically characterized by the up-regulation of T cell
costimulatory molecules (CD80, CD86) and the maturation marker (CD83). These
phenotypes are representative of five individual experiments. The percentage of
cells is shown above the histogram profile. Open histograms represent negative
control; solid histograms represent cells stained with the indicated, relevant mAb.
TABLE 2A. Differentiation of DC Generated from Two-Step, Cultured, Nonenriched HSC (106) or from One-Step,








HSC (106) Absolute number (106) % CD14 % CD1a % CD80 % CD86 % CD86 % CD83
Nonenriched IIa-1 2 5.4 40 17.6 36 21 49 26
Nonenriched IIa-2 2 2.8 63 20.5 50 47 65 34
Nonenriched IIa-3 2 5.3 72 17.7 86 77 69 24
Nonenriched IIa-4 2 10 78 21.7 63 69 84 29
Nonenriched IIa-5 2 10.1 24 18.3 66 73 43 14
Mean  SD 2 6.7  3.2 55.4  23 19.2  1.8 60  18.7 57.4  23.4 62  16.4 25.4  7.4
No. HSC (106)
imDC mDC
Absolute number (106) % CD14 % CD1a % CD80 % CD86 % CD86 % CD83
CD34-enriched IIa-1 2 5.1 13 13 23 28 31 16
CD34-enriched IIa-2 2 34.6 27 13.6 87 90 67 11
CD34-enriched IIa-3 2 33.3 18 6.5 66 75 77 17
CD34-enriched IIa-4 2 30 22 13.7 52 56 35 13
CD34-enriched IIa-5 2 5.2 18.4 4 28 88 65 22
Mean  SD 2 21.6  15.1 19.7  5.2 10.6  4.6 51.2  26.6 67.4  26 55  20.6 15.8  4.2
Data are from five individual experiments with nonenriched or enriched CD34 cells issued from the same G-CSF-mobilized patients. Absolute number of HSC
(Day 0 of the second-step culture) and DC (Day 8 and Day 10 of the second culture step) is shown. imDC, Immature DC; mDC, mature DC.
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ation rates with the nonenriched, two-step, cultured DC, par-
ticularly at the immature stage, as compared with enriched
CD34 DC (Fig. 5, A and B). Thus, the allostimulatory capacity
of DC generated by the nonenriched, two-step culture method
was at least as potent as that of purified CD34 DC. It must be
pointed out that the two types of DC induced much higher rates
of proliferation than peripheral mononuclear cells, even when
added at a 100-fold less ratio to responder T cells (Fig. 5B).
Generation of DC from nonenriched HSC by the
two-step culture method results in DC that
express similar phenotype than DC generated
from enriched CD34 HSC in a two-step
culture method
As HSC expansion during the first culture step requires the
presence of Flt-3L, which is a major cytokine in DC differen-
tiation [21–23], we then asked whether the faster differentia-
tion of HSC into DC could be related to the presence of this
cytokine for 15 days as opposed to 8 days only when no
expansion was performed. Therefore, to answer this question,
we compared the differentiating efficiency, starting from non-
enriched HSC versus enriched CD34 HSC and using the same
two-step culture method. As shown in Table 1B and similarly
to the results obtained in Table 1A, following expansion, the
percentage of CD34 cells increased markedly from 2% at
Day 0 to 26.9% at Day 7 in the nonenriched HSC culture while
staying at a high percentage (75%) in the enriched HSC
culture. In the second culture step, cells obtained by both
methods expressed similar levels of CD1a and CD14 (Fig. 6
and Table 2B). Accordingly, the levels of T cell costimulatory
molecules (CD80, CD86) were comparable in both cells (Fig. 6
and Table 2B). Finally, after LPS maturation, the CD86 and
TABLE 2B. Differentiation of DC Generated from Two-Step, Cultured, Nonenriched HSC (106) or from Two-Step,








HSC (106) Absolute number (106) % CD14 % CD1a % CD80 % CD86 % CD86 % CD83
Nonenriched IIb-1 2 4.8 73 13 52 8 65 26
Nonenriched IIb-2 2 2.8 88 5 80 62 71 8
Mean  SD 2 3.8  1.4 80  10.6 9  5.7 60  19.8 35  38 68  4.2 17  12.7
No. HSC (106)
imDC mDC
Absolute number (106) % CD14 % CD1a % CD80 % CD86 % CD86 % CD83
CD34-enriched IIb-1 2 4.8 70 11 30 51 65 11
CD34-enriched IIb-2 2 5.2 82 3 56 5 43 22
Mean  SD 2 5  0.2 76  8.5 7  5.7 43  18.4 28  32.5 54  15.6 16.5  0.5
Data are from two individual experiments with nonenriched or enriched CD34 cells issued from the same G-CSF-mobilized patients. Absolute number of HSC
(Day 0 of the second-step culture) and DC (Day 8 and Day 10 of the second-step culture) is shown.
Fig. 5. Allogeneic stimulatory capacity of DC generated with the nonenriched, two-step culture method is comparable with that of one-step, cultured, enriched
CD34 DC. T cells were stimulated in a primary MLR assay with graded doses of allogeneic DC generated from nonenriched but expanded HSC or enriched CD34
HSC. The number of allogeneic T cells per well was constant. The ratio of in vitro-generated DC to T cells varied from 1/20 to 1/160. Data are representative of
four independent MLR assays (four at Day 8 and four at Day 10). The denomination “imDC” corresponds to DC at Day 8 of the differentiated step, whereas “mDC”
corresponds to DC treated with LPS for 2 additional days. Data are represented as mean  SD of these four MLR assays (A). Data show one MLR representative
of four individual experiments (B).
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CD83 maturation marker was expressed at almost similar lev-
els in DC obtained by the nonenriched, two-step culture
method, as compared with enriched, two-step, cultured CD34
DC (Fig. 6 and Table 2B).
Generation of two-step, cultured DC from
nonenriched HSC results in higher yields of DC
as compared with two-step, cultured,
enriched CD34 DC
As the phenotype of DC derived from nonenriched HSC at Day
8 was at least as differentiated as that of enriched CD34 DC, we
compared the yields of DC obtained from both cultures by
calculating the absolute number of DC obtained per HSC. As
shown in Figure 7, a mean of 24.3 mature DC was obtained
from one CD34 HSC using the nonenriched HSC culture
method as compared with 3.6 mature DC/HSC, starting from
enriched CD34 HSC. Therefore, these results indicate that the
nonenriched HSC culture method is the most efficient in gen-
erating mature DC from HSC precursors.
DISCUSSION
In the current study, we developed a new culture method for
generating large numbers of DC from hematopoietic progenitor
cells without prior HSC enrichment. We divided the culture
method into two steps. The first step aimed to initially expand
HSC harvested from G-CSF-mobilized blood without prior pu-
rification of hematopoietic progenitors. Therefore, MNC were
separated by gradient density and were cultured in the pres-
ence of cytokines known to favor the expansion of hematopoi-
etic progenitors such as SCF, Flt-3L, and TPO. The second
step was a DC differentiation phase in the presence of cyto-
kines such as GM-CSF, Flt-3L, and TNF-. This new, nonen-
riched, two-step culture method resulted first in a marked
amplification of CD34/CD38/Linneg HSC after 7 days of
culture and then in the differentiation of the expanded HSC
into functional DC. In addition, these DC were able to mature
by signaling through TLR4, which recognizes LPS.
Fig. 6. DC generated by the nonenriched, two-step culture method present a similar phenotype than two-step, cultured, enriched CD34 DC. At the end of the
second step of culture, DC were stained for CD1a and CD14 expression. The levels of expression of these molecules were compared by cytofluorometry with that
of enriched CD34 DC in two-step culture. This phenotype is representative of two individual experiments. Quadrants were set up on the isotype-matched control
dot plot, and 10,000 events were acquired. The percentage of nongated cells is shown in the dot-plot profiles. At Day 8, cells were induced to mature by exposure
to 100 ng/ml LPS for 48 h. These phenotypes are representative of two individual experiments. The percentage of cells is shown above the histogram profile. Open
histograms represent negative controls; solid histograms represent cells stained with the indicated, relevant mAb.
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G-CSF mobilizes hematopoietic progenitor cells from bone
marrow to the peripheral blood and also promotes the matura-
tion of myeloid cells. G-CSF-mobilized MNC comprise a major
fraction of committed hematopoietic cells and a minor fraction
of hematopoietic progenitor cells, which are mostly CD34/
CD38/Linneg. Hence, using G-CSF-mobilized MNC as a di-
rect source for expanding HSC circumvents the need for stem
cell enrichment prior to expansion, thereby simplifying the
process substantially in terms of efficiency and cost. In this
study, only 2% of CD34 cells were present in G-CSF-
mobilized MNC, but the percentage of CD34 cells increased
up to 29% after 7 days of culture with early acting cytokines.
However, this high percentage of CD34 cells was transient,
as it decreased from Day 7 to Day 14 of the first step of culture.
Therefore, to take advantage of this rapid and strong CD34/
CD38/Linneg HSC expansion, we defined the optimum period
for differentiating HSC into DC to be at Day 7 of the first step
of culture.
The well-established, standard, one-step method of DC gen-
eration from CD34 precursors gives rise, after 8 days of
culture, to two distinct populations of DC: the CD1aCD14–
cells, which are precursors of Langerhans cells, and the
CD14CD1a– cells, which are precursors of interstitial DC [1,
9–11]. In this study, DC generated from nonenriched, G-CSF-
mobilized MNC or from enriched CD34 cells were obtained
from the same donors and were thus comparable. During the
differentiation step of this new method, DC were generated
earlier and at higher rates from expanded, nonenriched HSC as
compared with the enriched CD34, one-step culture method.
Indeed, DC generated from purified-CD34 HSC did not
express CD1a and CD14 markers before Day 8 of culture. On
the contrary, DC generated from expanded but nonenriched
HSC showed CD14- or CD1a-positive cells on the fifth day of
the second culture step, and the percents increased up to Day
8. It has been reported by Caux et al. [2] that the appearance
of a double-positive CD14CD1a population correlates with
the progressive disappearance of the CD14CD1a– popula-
tion, demonstrating that double-positive cells arise from
CD14 cells, which then acquire the CD1a marker. In our
nonenriched, two-step culture method, the percentage of dou-
Fig. 7. DC generated by the nonenriched, two-step culture method results in larger yields than two-step, cultured, enriched CD34 DC. This figure represents a
scheme of the different steps used to culture enriched CD34 DC and nonenriched DC, respectively. Starting from 200  106 G-CSF-mobilized MNC apheresis,
two batches of 2  106 HSC (after CD34 enrichment by a Miltenyi column) or 100  106 HSC for the enriched culture or the nonenriched culture method were
seeded, respectively. Absolute numbers of HSC were calculated at the end of the first culture step by multiplying the mean of expansion during the first culture
step (six for enriched HSC and 1.8 for nonenriched HSC, respectively) with the percentage of CD34 cells (73% for enriched HSC and 26.9% for nonenriched
HSC, respectively). Absolute numbers of DC were calculated at the end of the second-step culture method by multiplying the mean of expansion during the second
culture step (five for enriched HSC and 5.9 for nonenriched HSC, respectively) with the absolute number of HSC. Then, ratios of DC per HSC were calculated,
as well as ratio of mature DC per HSC.
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ble-positive cells was higher (4.3–14.1%) than that of en-
riched, one-step, cultured CD34 DC (0.9–5.1%), suggesting
that the nonenriched, two-step, cultured DC were more differ-
entiated.
CD34 HSC have been shown to proliferate during differ-
entiation into DC [2]. The fold increase during the differenti-
ation step of enriched CD34 DC was of 10.8  7.5 (meanSD)
and 2.5  0.1 (meanSD) for enriched, two-step CD34 DC
versus 2.9  1.5 (meanSD) for DC generated by the nonen-
riched, two-step culture method and starting from the same
amount of MNC in the initial culture. These data indicate thus
that this new, nonenriched, two-step culture method leads to
generation of higher yields of cells expressing a DC phenotype,
as compared with the one-step culture method using enriched
CD34 HSC. As the percentage of mature DC was higher with
the nonenriched HSC two-step culture method as compared
with the enriched HSC classical method, 34% versus 11%, re-
spectively, our data suggest that this new, nonenriched, two-step
culture method should lead to generation of more mature DC.
This rapid differentiation of HSC into mature DC, even
without prior enrichment, could be related to the expansion
step, as Flt-3L was present for 15 days during culture of
nonenriched, two-step-generated DC, as compared with 8 days
only during culture of enriched, one-step, cultured DC. Indeed,
Flt-3L is known to trigger stimulation of Flt-3 receptor tyrosine
kinase, which leads to expansion of early hematopoietic pro-
genitors, but also of DC in human and mice [19–21]. In
particular, in vitro or in vivo administration of Flt-3L drives
Flt-3 DC development from Flt-3 progenitors [19–21]. To
test this hypothesis, we performed a two-step culture compar-
ing enriched and nonenriched cells in parallel. The results
showed indeed that the phenotype of DC from enriched or
nonenriched cells, obtained after 15 days of two-step culture,
was comparable for CD14, CD1a, CD80, and CD86 markers,
suggesting that the cytokines used in the expansion step are
helping DC differentiation as well. It is interesting that the
CD83 marker was expressed at similar percentage in both
cells, assessing thus that Flt-3L may play an important role in
the facilitation of DC generation and maturation.
TNF- participates in the maturation process but is not
sufficient by its own to stimulate the terminal differentiation of
DC generated from CD34 HSC. In previous studies, low or
undetectable levels of CD83 expression in Day 8-generated
CD34 DC have been described [22–26]. Accordingly, we ob-
served that the CD83 maturation marker was expressed at low
levels at the surface of enriched CD34 DC in one-step culture.
Using the nonenriched, two-step culture method, we have been
able to generate more differentiated DC, as up to 17% of the
cells expressed CD83 prior to exposure to LPS, as compared
with up to only 4% with the standard, enriched, one-step
culture method. When we attempted to induce maturation of
these DC by using LPS, the levels increased up to 34% with
the nonenriched, two-step culture method, as compared with
11% with the standard, enriched, one-step culture method. In
most instances, TLR4 stimulation by LPS favors the develop-
ment of a Th1 response, particularly through IL-12 secretion
[27]. In the particular case of enriched CD34 DC, LPS has
been shown to mobilize MHC Classes I and II molecules from
late endosomes to the cell surface, following activation of
CD34 Langerhans cells [28–29]. In addition, the efficacy of
TLR4-mediated DC maturation was shown in a murine antitu-
mor vaccination study [30]. Last, Blander and Medzhitov [31]
have shown recently that phagocytosed particles with LPS
contained stable MHC Class II molecules with indications of
advanced stages of antigen processing, which suggests useful-
ness of LPS in the design of new vaccines.
Generation of higher amounts of DC by a two-step culture
method has been reported already, using cord blood or bone
marrow HSC [15, 16]. However, these protocols required en-
richment of CD34 cells and a 2-week expansion step before
differentiating them into DC. Here, we found that expansion
during 7 days only is sufficient to allow production of marked
levels of HSC, even when starting from low percentages of
CD34 cells and that these cells differentiate into mature DC
at high rates. Therefore, as compared with the other methods,
our protocol is of particular interest when the amount of
CD34 cells harvested from G-CSF-mobilized blood is too low
to allow enrichment. Indeed, in patients who undergo multiple
chemotherapies, mobilization of HSC is known to be less
efficient and thus, does not easily allow CD34 HSC purifi-
cation. Thus, when we addressed the possibility of obtaining
DC, using cells from a patient who has been treated intensively
with multiple chemotherapies for lymphoma, we have been
able to generate significant amounts of DC from nonenriched,
G-CSF-mobilized MNC, although at a lower yield than that
usually obtained with healthy donors (data not shown). There-
fore, as the range of DC injected per kg body weight varies from
0.1 to 1  106/kg body weight in clinical settings, this new
method should allow sufficient amounts of DC to be obtained
for cell therapy programs, even when poor grafts are obtained.
Further experiments are planned to compare different media,
particularly serum-free medium, to optimize the culture
method.
In conclusion, this study provides a novel strategy for easily
generating large numbers of DC from hematopoietic progeni-
tors without any need of HSC purification. DC were generated
from nonenriched, G-CSF-mobilized MNC by a two-step cul-
ture method and were shown to differentiate and mature effi-
ciently at the phenotypical and functional levels. These find-
ings might have implications into the use of DC as adjuvants
for cell immunotherapy.
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